Sutro Biopharma STRO Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's short- and long-term operating lease liabilities?
- Sutro Biopharma (STRO) reported short- and long-term operating lease liabilities of -$2.04M in Q1 2026.
- How has Sutro Biopharma's short- and long-term operating lease liabilities changed year-over-year?
- Sutro Biopharma's short- and long-term operating lease liabilities decreased by 16.2% year-over-year, from -$1.76M to -$2.04M.
- What is the long-term trend for Sutro Biopharma's short- and long-term operating lease liabilities?
- Over 4 years (2021 to 2025), Sutro Biopharma's short- and long-term operating lease liabilities has grown at a 28.7% compound annual growth rate (CAGR), from -$2.73M to -$7.48M.